γ-linolenic acid (Borage Oil) / P53 Cancer Research Results

GLA, γ-linolenic acid (Borage Oil): Click to Expand ⟱
Features:

γ-Linolenic acid (GLA) — an omega-6 polyunsaturated fatty acid (18:3 n-6) found in high concentration in borage oil, evening primrose oil, and blackcurrant seed oil. Metabolized to dihomo-γ-linolenic acid (DGLA) → precursor of anti-inflammatory eicosanoids (e.g., PGE1).

Primary mechanisms (conceptual rank):
1) Membrane lipid remodeling → altered eicosanoid balance (↑ PGE1; DGLA-derived metabolites)
2) Modulation of inflammatory signaling (↓ NF-κB tone; context-dependent)
3) Lipid peroxidation susceptibility (PUFA-driven ROS shifts)
4) Potential anti-proliferative effects (high concentration only; tumor models)
5) Metabolic signaling interaction (PPAR activation context-dependent)

Bioavailability / PK relevance: Orally absorbed and incorporated into membrane phospholipids; rapidly elongated to DGLA. Plasma levels achievable with supplementation; cellular effects reflect incorporation over days–weeks (remodeling).

In-vitro vs oral exposure: Direct tumor cytotoxicity generally observed at supra-physiologic concentrations; physiologic doses mainly alter lipid signaling rather than induce apoptosis.

Clinical evidence status: Used for inflammatory conditions (e.g., dermatitis, RA); oncology data limited and inconsistent; no cancer approval.

GLA (abundant in borage oil) has shown anti-proliferative and pro-apoptotic effects on multiple cancer cell lines and in animal models (mechanisms include ER stress, mitochondrial dysfunction, altered eicosanoid signaling).
-Borage plants can contain unsaturated PAs(Pyrrolizidine alkaloids) which are hepatotoxic and genotoxic/carcinogenic. Many authorities advise only using borage oil products certified PA-free, and caution against long-term or high-dose use.
-γ-gamma linolenic acid (GLA, 18:3n-6) are polyunsaturated fatty acids (PUFA) that improve the human health

γ-Linolenic Acid (Borage Oil) — Cancer vs Normal Cell Pathway Map

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Membrane lipid remodeling (DGLA incorporation) ↑ substrate (context-dependent) ↑ membrane incorporation G Phospholipid composition shift Changes membrane fluidity and eicosanoid substrate pool; time-dependent remodeling.
2 Eicosanoid balance (PGE1 vs AA-derived eicosanoids) ↔ / ↓ pro-inflammatory tone ↓ inflammation G Anti-inflammatory modulation DGLA-derived PGE1 often anti-inflammatory; may counterbalance arachidonic acid metabolites.
3 ROS / Lipid peroxidation ↑ (PUFA-dependent; dose-dependent) ↔ / ↑ (high dose) P/R Lipid oxidative susceptibility Highly unsaturated structure increases peroxidation potential; may sensitize tumors to oxidative stress.
4 NF-κB ↓ (context-dependent) ↓ R/G Reduced inflammatory transcription Often secondary to altered eicosanoid signaling.
5 PPAR (α/γ) ↑ (model-dependent) ↑ R/G Lipid metabolic regulation GLA and derivatives may activate PPAR pathways influencing lipid and glucose metabolism.
6 Apoptosis ↑ (high concentration only) ↔ R/G Mitochondrial apoptosis (experimental) Reported in certain tumor lines at supra-physiologic levels.
7 Ferroptosis ↑ (theoretical; PUFA-linked) ↔ R/G Lipid peroxidation vulnerability PUFA enrichment can enhance ferroptotic susceptibility depending on antioxidant context.
8 HIF-1α ↔ (limited evidence) ↔ G Not primary axis No consistent direct modulation reported.
9 NRF2 ↔ / ↑ (adaptive; context-dependent) ↔ R/G Redox-response adjustment May activate antioxidant response secondary to lipid peroxidation stress.
10 Ca²⁺ signaling ↔ (membrane-dependent) ↔ P/R Membrane microdomain modulation Changes in lipid composition can subtly influence ion channel behavior.
11 Clinical Translation Constraint ↓ (constraint) ↓ (constraint) — Context-dependent effects Physiologic doses primarily anti-inflammatory; anti-cancer cytotoxicity not clinically established.

TSF legend:
P: 0–30 min (lipid oxidation events)
R: 30 min–3 hr (acute signaling shifts)
G: >3 hr (membrane remodeling and phenotype changes)
P53, P53-Guardian of the Genome: Click to Expand ⟱
Source: TCGA
Type: Proapototic
TP53 is the most commonly mutated gene in human cancer. TP53 is a gene that encodes for the p53 tumor suppressor protein ; TP73 (Chr.1p36.33) and TP63 (Chr.3q28) genes that encode transcription factors p73 and p63, respectively, are TP53 homologous structures.
p53 is a crucial tumor suppressor protein that plays a significant role in regulating the cell cycle, maintaining genomic stability, and preventing tumor formation. It is often referred to as the "guardian of the genome" due to its role in protecting cells from DNA damage and stress.
TP53 gene, which encodes the p53 protein, is one of the most frequently mutated genes in human cancers.
Overexpression of MDM2, an inhibitor of p53, can lead to decreased p53 activity even in the presence of wild-type p53.
In some cancers, particularly those with mutant p53, there may be an overexpression of the p53 protein.
Cancers with overexpression: Breast, lung, colorectal, overian, head and neck, Esophageal, bladder, pancreatic, and liver.
Scientific Papers found: Click to Expand⟱
4510- GLA,    Gamma-linolenic acid therapy of human glioma-a review of in vitro, in vivo, and clinical studies
- Review, NA, NA
Apoptosis↑, selectivity↑, eff↓, ROS↑, lipid-P↑, P53↑, radioP↑, chemoP↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

lipid-P↑, 1,   ROS↑, 1,  

Cell Death ⓘ

Apoptosis↑, 1,  

DNA Damage & Repair ⓘ

P53↑, 1,  

Drug Metabolism & Resistance ⓘ

eff↓, 1,   selectivity↑, 1,  

Functional Outcomes ⓘ

chemoP↑, 1,   radioP↑, 1,  
Total Targets: 8

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: P53, P53-Guardian of the Genome
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:374  Target#:236  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page